EGFR uncommon mutations (G719X / S768I / L861Q)
Gene: EGFR · Type: mutation
Indications: Non-small cell lung cancer
Linked CIViC Profile: EGFR
Evidence Level Distribution
Level A: 28Level B: 94Level C: 64Level D: 77Level E: 2
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| D | Predictive | Supports | Resistance | Lung Cancer | Multikinase Inhibitor AEE788,Gefitinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Ramucirumab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib,Chemotherapy | 5 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Dacomitinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |